Cerity Partners
INFI

Cerity Partners’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Cerity Partners’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$1.6K – 2004
2023
Q1 		$1.6K Hold
10,000
– – ﹤0.01% 1843
2022
Q4 		$5.55K Buy
+10,000
New +$8.51K ﹤0.01% 1477

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cerity Partners's INFI Position: Q2 2023 in Review

Cerity Partners sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2023, closing a stake of 10,000 shares — an estimated $1.6K sold.

Cerity Partners first reported a position in INFI in Q4 2022 and held it in 2 quarters. The position peaked at $5.55K in Q4 2022. 45 funds tracked by Wall St. Rank hold INFI as of Q2 2023.

  • Cerity Partners reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Cerity Partners sold 10,000 Infinity Pharmaceuticals, Inc. shares in Q2 2023, an estimated $1.6K.
  • Cerity Partners first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2022 and held it in 2 quarters.
  • Cerity Partners's Infinity Pharmaceuticals, Inc. position peaked at $5.55K in Q4 2022.
  • 45 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2023.

Based on Cerity Partners's 13F filing for Q2 2023, filed 14 Aug 2023.